Company intelligence / Profile preview

Kelliop

Ownership: Private
Employees: ~1
Development stage: Commercial

Overview

Kelliop develops lab-on-chip diagnostic platforms that enable rapid, sensitive, high-throughput sample-to-answer solutions for molecular and genomic testing. Their technology leverages qPCR, ddPCR, and sequencing to simplify complex laboratory procedures into fast point-of-care or near-patient workflows. Clinical results are not directly reported as the company provides diagnostic tools rather than therapeutics.

Therapeutic areas: Other
Modalities: DeviceMolecular diagnostics platformqPCR (quantitative PCR)ddPCR (digital droplet PCR)Sequencing-based diagnostics
Industry: Molecular Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships disclosed in available sources.

Beyond the preview

Go deeper on Kelliop.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelliop.

Explore the full profile